(Q40534342)

21 September 2017

title

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia (English)

1 reference

21 September 2017

1 reference

1 reference

Geir Erland Tjønnfjord

series ordinal

4

object named as

Geir E Tjonnfjord

1 reference

21 September 2017

3

Tobias Gedde Dahl

1 reference

21 September 2017

Waleed Ghanima

1

1 reference

21 September 2017

Johannes Kahrs

series ordinal

2

1 reference

21 September 2017

publication date

1 June 2004

1 reference

European Journal of Haematology

21 September 2017

published in

1 reference

21 September 2017

volume

72

1 reference

21 September 2017

issue

6

1 reference

21 September 2017

page(s)

441-443

1 reference

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00257.X

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00257.X

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00257.X

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00257.X

10.1111/J.1600-0609.2004.00257.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference